EGFR and non-small cell lung carcinoma: EGFR mutants have been reported more frequently in NSCLC in nonsmokers Asians patients and showed highly sensitive to therapy with EGFR tyrosine kinase inhibitors such as gefitinib and erlotinib (4, 5).